Literature DB >> 2004444

Quantification of plasma lipoproteins by proton nuclear magnetic resonance spectroscopy.

J D Otvos1, E J Jeyarajah, D W Bennett.   

Abstract

A new analytical procedure for quantifying plasma lipoproteins by proton nuclear magnetic resonance (NMR) spectroscopy has been developed that potentially offers significant advantages over existing clinical methods used for assessing risk of coronary heart disease. Analysis of a single spectrum of a nonfasting plasma sample, acquired simply and rapidly at moderate magnetic field strength (250 MHz), yields a complete profile of lipoprotein concentrations: chylomicrons and very-low-, low-, and high-density lipoproteins. The method is based on curve-fitting (spectral deconvolution) of the plasma methyl lipid resonance envelope, the amplitude and shape of which depend directly on the amplitudes of the superimposed methyl resonances of the lipoprotein components. A linear least-squares curve-fitting algorithm was developed to efficiently extract the signal amplitudes (concentrations) of the lipoproteins from the plasma spectrum. These signal amplitudes correlate well with lipoprotein concentrations determined by triglyceride and cholesterol measurements.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2004444

Source DB:  PubMed          Journal:  Clin Chem        ISSN: 0009-9147            Impact factor:   8.327


  46 in total

Review 1.  Specialized lipid profiles.

Authors:  Karen E Friday
Journal:  Curr Atheroscler Rep       Date:  2002-09       Impact factor: 5.113

2.  How complicated can it be? The link between APOL1 risk variants and lipoprotein heterogeneity in kidney and cardiovascular diseases.

Authors:  Chien-An A Hu; Patricio E Ray
Journal:  Nephrol Dial Transplant       Date:  2015-10-03       Impact factor: 5.992

3.  1H NMR spectroscopy quantifies visibility of lipoproteins, subclasses, and lipids at varied temperatures and pressures.

Authors:  Daniela Baumstark; Werner Kremer; Alfred Boettcher; Christina Schreier; Paul Sander; Gerd Schmitz; Renate Kirchhoefer; Fritz Huber; Hans Robert Kalbitzer
Journal:  J Lipid Res       Date:  2019-06-25       Impact factor: 5.922

Review 4.  Lipid parameters for measuring risk of cardiovascular disease.

Authors:  Benoit J Arsenault; S Matthijs Boekholdt; John J P Kastelein
Journal:  Nat Rev Cardiol       Date:  2011-02-01       Impact factor: 32.419

5.  Quantitative analysis of blood plasma metabolites using isotope enhanced NMR methods.

Authors:  G A Nagana Gowda; Fariba Tayyari; Tao Ye; Yuliana Suryani; Siwei Wei; Narasimhamurthy Shanaiah; Daniel Raftery
Journal:  Anal Chem       Date:  2010-09-29       Impact factor: 6.986

6.  APOL1 nephropathy risk variants are associated with altered high-density lipoprotein profiles in African Americans.

Authors:  Orlando M Gutiérrez; Suzanne E Judd; Marguerite R Irvin; Degui Zhi; Nita Limdi; Nicholette D Palmer; Stephen S Rich; Michèle M Sale; Barry I Freedman
Journal:  Nephrol Dial Transplant       Date:  2015-07-06       Impact factor: 5.992

7.  HDL cholesterol is not HDL--don't judge the book by its cover.

Authors:  Benoit J Arsenault; Jean-Pierre Després
Journal:  Nat Rev Cardiol       Date:  2012-09-04       Impact factor: 32.419

8.  Lipoprotein particles, insulin, adiponectin, C-reactive protein and risk of coronary heart disease among men with metabolic syndrome.

Authors:  Lewis H Kuller; Gregory Grandits; Jerome D Cohen; James D Neaton; Ronald Prineas
Journal:  Atherosclerosis       Date:  2006-10-02       Impact factor: 5.162

9.  High throughput prediction of chylomicron triglycerides in human plasma by nuclear magnetic resonance and chemometrics.

Authors:  Francesco Savorani; Mette Kristensen; Flemming H Larsen; Arne Astrup; Søren B Engelsen
Journal:  Nutr Metab (Lond)       Date:  2010-05-14       Impact factor: 4.169

Review 10.  Metabolomics-based methods for early disease diagnostics.

Authors:  G A Nagana Gowda; Shucha Zhang; Haiwei Gu; Vincent Asiago; Narasimhamurthy Shanaiah; Daniel Raftery
Journal:  Expert Rev Mol Diagn       Date:  2008-09       Impact factor: 5.225

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.